Acadia Pharmaceuticals Stock In The News

ACAD Stock  USD 16.37  0.19  1.17%   
Our overall analysis of ACADIA Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards ACADIA Pharmaceuticals. The specific impact of ACADIA Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of ACADIA Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using ACADIA Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out ACADIA Pharmaceuticals Backtesting and ACADIA Pharmaceuticals Hype Analysis.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

ACADIA Pharmaceuticals Today Top News and Investor Outlook

Yahoo News
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
https://finance.yahoo.com/news/acadia-pharmaceuticals-announce-third-quarter-224100345.html
 Bullish
Yahoo News
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUEâ„¢ (trofinetide) for the Treatment of Rett Syndrome
https://finance.yahoo.com/news/acadia-pharmaceuticals-announces-health-canada-200700205.html
 Bullish
Yahoo News
Are ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
https://finance.yahoo.com/news/acadia-pharmaceuticals-inc-nasdaq-acad-105535166.html
 Bullish
Yahoo News
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://finance.yahoo.com/news/acadia-pharmaceuticals-reports-inducement-grants-200500598.html
 Bullish
Yahoo News
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
https://finance.yahoo.com/news/catherine-owen-adams-succeeds-steve-201500419.html
 Bullish
Yahoo News
High Growth Tech Stocks To Watch In September 2024
https://finance.yahoo.com/news/high-growth-tech-stocks-watch-100241465.html
 Bullish
Yahoo News
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
https://finance.yahoo.com/news/implied-volatility-surging-acadia-pharmaceuticals-123000843.html
 Bullish
Yahoo News
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
https://finance.yahoo.com/news/acadia-pharmaceuticals-participate-upcoming-investor-200500677.html
 Neutral
Yahoo News
Shareholders Can Be Confident That ACADIA Pharmaceuticals' (NASDAQ:ACAD) Earnings Are High Quality
https://finance.yahoo.com/news/shareholders-confident-acadia-pharmaceuticals-nasdaq-104756841.html
 Bullish
Yahoo News
ACADIA Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
https://finance.yahoo.com/news/acadia-pharmaceuticals-second-quarter-2024-113112902.html
 Neutral

ACADIA Pharmaceuticals Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide ACADIA and other traded companies coverage with news coverage. We help investors stay connected with ACADIA headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on ACADIA Stock performance. Please note that trading solely based on the ACADIA Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
ACADIA Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help ACADIA Pharmaceuticals investors visualize upcoming and past events in order to time the market based on ACADIA Pharmaceuticals noise-free hype analysis.
ACADIA Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the ACADIA earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about ACADIA Pharmaceuticals that are available to investors today. That information is available publicly through ACADIA media outlets and privately through word of mouth or via ACADIA internal channels. However, regardless of the origin, that massive amount of ACADIA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ACADIA Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ACADIA Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ACADIA Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ACADIA Pharmaceuticals alpha.

ACADIA Largest EPS Surprises

Earnings surprises can significantly impact ACADIA Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-06
2024-06-300.180.20.0211 
2022-11-02
2022-09-30-0.19-0.170.0210 
2013-08-06
2013-06-30-0.09-0.11-0.0222 
2013-03-12
2012-12-31-0.09-0.11-0.0222 
2012-08-08
2012-06-30-0.12-0.10.0216 
2011-08-10
2011-06-30-0.14-0.120.0214 
View All Earnings Estimates

ACADIA Pharmaceuticals Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to ACADIA Pharmaceuticals Stock. Current markets are strongly bullish. About 82% of major world exchanges and indexes are currently up. See today's market update for more information.
Gurufocus Stories at Macroaxis
21st of November 2024
ACADIA HEALTHCARE SHAREHOLDER ALERT CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF...
at gurufocus.com 
Gurufocus Stories at Macroaxis
19th of November 2024
Disposition of 10259 shares by Mark Schneyer of ACADIA Pharmaceuticals at 16.81 subject to...
at gurufocus.com 
news
15th of November 2024
ACADIA Pharmaceuticals Downgraded to Buy Rating by StockNews.com
at thelincolnianonline.com 
news
12th of November 2024
WCM Investment Management LLC Has 4.50 Million Holdings in ACADIA Pharmaceuticals Inc.
at thelincolnianonline.com 
insidermonkey News
8th of November 2024
ACADIA Pharmaceuticals Inc. Q3 2024 Earnings Call Transcript
at insidermonkey.com 
Yahoo News
7th of November 2024
Acadias Q3 Earnings Beat, Nuplazid Daybue Drive Revenue Growth
at finance.yahoo.com 
Investing News at Macroaxis
6th of November 2024
ACADIA earnings beat by 0.06, revenue topped estimates
at investing.com 
businesswire News
21st of October 2024
ACADIA HEALTHCARE SHAREHOLDER ALERT by Former Louisiana Attorney General Kahn Swick Foti, ...
at businesswire.com 
zacks News
9th of October 2024
ACAD or TECH Which Is the Better Value Stock Right Now
at zacks.com 
businesswire News
23rd of September 2024
ACADIA HEALTHCARE INVESTOR ALERT ScottScott Attorneys at Law LLP Investigates Marathon Pet...
at businesswire.com 

ACADIA Pharmaceuticals Investors Sentiment

The influence of ACADIA Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in ACADIA. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to ACADIA Pharmaceuticals' public news can be used to forecast risks associated with an investment in ACADIA. The trend in average sentiment can be used to explain how an investor holding ACADIA can time the market purely based on public headlines and social activities around ACADIA Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ACADIA Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ACADIA Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average ACADIA Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on ACADIA Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ACADIA Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ACADIA Pharmaceuticals' short interest history, or implied volatility extrapolated from ACADIA Pharmaceuticals options trading.
When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:
Check out ACADIA Pharmaceuticals Backtesting and ACADIA Pharmaceuticals Hype Analysis.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
28.347
Earnings Share
0.78
Revenue Per Share
5.622
Quarterly Revenue Growth
0.183
Return On Assets
0.0872
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.